Phorbol Ester Derivatives Modulating Cell Signaling for Reduced Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medicinal approaches face challenges in isolating and commercializing specific plant-derived compounds, such as phorbol esters, due to their complex composition and potential toxicity, limiting their effectiveness in treating chronic and acute diseases, including HIV, cancer, and inflammatory conditions.
Innovation Solution
Compositions and methods utilizing phorbol esters and their derivatives to modulate cell signaling pathways, treat diseases, and manage symptoms by modifying HIV receptor activity, decreasing latent HIV reservoirs, and inhibiting HIV-cytopathic effects, while also addressing side effects of chemotherapy and radiation therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If phorbol esters are used to treat diseases, then therapeutic effectiveness is improved, but toxicity and harmful side effects increase
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of phorbol esters through substitution at specific positions (such as introducing electron-withdrawing groups like fluorine, chlorine, or nitro groups) to alter their biological activity profile. This reduces tumor-promoting and toxic effects while preserving or enhancing antiviral and anticancer therapeutic effects. The systematic variation of molecular parameters allows optimization of the therapeutic index.
Solution Approach 2:
The patent segments the phorbol ester molecule by introducing substituents at specific positions (C-2, C-6, C-22, etc.) to create distinct functional regions. This segmentation allows different parts of the molecule to contribute differently to therapeutic activity versus toxicity, enabling selective modulation of biological effects through targeted structural modifications.
2Reliability
If plant-based compounds are isolated and commercialized, then medicinal effectiveness is improved, but complexity of purification and commercialization increases
Solution Approach 1:
The patent extracts and isolates specific phorbol ester compounds from complex plant matrices (such as Croton tiglium seeds) through systematic purification processes. This extraction approach separates the active therapeutic components from other plant constituents, enabling commercialization of standardized, potent formulations with defined efficacy while simplifying manufacturing.
3Reliability
If phorbol esters are used to activate protein kinase C, then cellular response is improved, but inflammatory responses and tumor development increase
Solution Approach 1:
The patent converts the harmful tumor-promoting and pro-inflammatory effects of phorbol esters into beneficial therapeutic outcomes by using structurally modified derivatives that selectively activate protein kinase C in antiviral and anticancer contexts. The modified compounds harness the cellular signaling capability while eliminating or reducing the harmful inflammatory and tumorigenic responses through careful molecular design.
Data Source
AI summary
Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.